Illumina Inc

Most Recent

  • Illumina Buying Cancer Test Company Grail
    Healthcare

    Illumina To Buy Cancer Testing Firm Grail For $8 Billion

    By Ambrish Shah
  • uploads///Com
    Company & Industry Overviews

    Signet Jewelers and Illumina Rose on November 27

    Signet Jewelers (SIG), the world’s largest diamond jewelry retailer, was the S&P 500’s second-best performer on November 27.

    By Val Kensington
  • uploads///microbiology _
    Company & Industry Overviews

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

    By Sarah Collins
  • uploads///ORCL
    Materials

    Highfields Capital starts new positions in ASH, NWSA, MU, and CF and sells ILMN and ORCL—13F Flash F

    Highfields Capital Management, LP, is a privately owned value-oriented investment management firm. Why sell Oracle Corp. (ORCL)?

    By Samantha Nielson
  • uploads///AdobeStock_
    Earnings Report

    Here’s What Pressured Illumina Stock after Its Q2 Results

    Yesterday, genome-sequencing company Illumina (ILMN) reported its second-quarter earnings results after the market closed.

    By Margaret Patrick
  • uploads///ILMN
    Company & Industry Overviews

    Analysts Remain Bullish on Illumina Stock

    In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Gross Margin Trend

    Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Geographical Performance

    For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

    By Kenneth Smith
  • uploads///hands _
    Company & Industry Overviews

    Pacific Biosciences of California Rose 67.63% on November 2

    On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

    By Kenneth Smith
  • uploads///hologic recommendations
    Company & Industry Overviews

    Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock

    As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

    By Sarah Collins
  • uploads///paper _
    Company & Industry Overviews

    20 Earnings Reports to Watch for This Week

    Earnings season is in full swing, and the week of April 23 is jam-packed with releases by some of the market’s most popular companies. Here are 20 reports we will be watching closely next week: Monday, April 23: Hasbro, Inc. (NASDAQ: HAS) – before the market opens -will they say anything about Mattel with the […]

    By JP Gravitt
  • uploads///family _
    Company & Industry Overviews

    What Analysts Recommend for Amedisys and Peers in March 2018

    Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///MASI
    Company & Industry Overviews

    Masimo’s Geographic Segments in Fiscal 2017

    In fiscal 2017, Masimo generated an operating cash flow of $56 million—compared to $419.1 million in fiscal 2016.

    By Kenneth Smith
  • uploads///microscope _
    Company & Industry Overviews

    Masimo and Its Peers: Analysts’ Ratings in March 2018

    Of the five analysts covering Masimo in March 2018, two analysts gave the stock a “strong buy” rating, while three analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///ambulance __
    Company & Industry Overviews

    Analyst Ratings for BioTelemetry and Its Peers in March 2018

    Of the seven analysts covering BioTelemetry in March 2018, two have given it a “strong buy” rating, and five have given it a “buy.”

    By Kenneth Smith
  • uploads///BEAT
    Company & Industry Overviews

    Understanding BioTelemetry’s Business Strategy

    BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services.

    By Kenneth Smith
  • uploads///stock price
    Company & Industry Overviews

    A Look at Thermo Fisher Scientific’s Recent Stock Price Performance

    TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.

    By Sarah Collins
  • uploads///GENETIC ANALYSIS GROWTH STRATEGY
    Company & Industry Overviews

    TMO’s Launch of New Research Assay for Cancer

    On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.

    By Sarah Collins
  • uploads///quantstudio
    Company & Industry Overviews

    Thermo Fisher Expands Its Partnership with Genome Diagnostics

    In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.

    By Sarah Collins
  • uploads///life sciences strategy
    Company & Industry Overviews

    Latest Product Launch Expands BD’s Genomics Portfolio

    Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.

    By Sarah Collins
  • uploads///Chart  OP
    Company & Industry Overviews

    How Gilead’s Other Products Performed in 2Q17

    Apart from Gilead Sciences’ (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio.

    By Mike Benson
  • uploads///life sciences group
    Company & Industry Overviews

    Thermo Fisher Scientific Accelerates Its Semiconductor Sequencing

    On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.

    By Sarah Collins
  • uploads///LIFESCIENCES PIPELINE
    Company & Industry Overviews

    BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth

    Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.

    By Sarah Collins
  • uploads///nus pm
    Company & Industry Overviews

    Sidoti Upgrades Nu Skin Enterprises to ‘Buy’

    Price movement Nu Skin Enterprises (NUS) has a market cap of $2.7 billion. It rose 3.1% to close at $49.32 per share on December 8, 2016. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were -1.8%, -7.9%, and 34.7%, respectively, on the same day. NUS is trading 6.3% below its 20-day moving average, […]

    By Gabriel Kane
  • uploads///nus pm
    Company & Industry Overviews

    Nu Skin Enterprises Made Changes in Its Management

    Nu Skin Enterprises (NUS) has a market cap of $2.6 billion. It fell 7.2% to close at $47.85 per share on December 7, 2016.

    By Gabriel Kane
  • uploads///Portfolio Breakdown of the ELGAX
    Fund Managers

    Columbia Select Large Cap Growth Fund: Sector Composition YTD 2016

    The Columbia Select Large Cap Growth Fund (ELGAX) invests at least 80% of its assets in common stocks of US-based and foreign companies with market caps in the range of companies in the Russell 1000 Growth Index.

    By David Ashworth
  • uploads///nus pm
    Company & Industry Overviews

    Nu Skin Enterprises Receives Investment of $210 Million

    Nu Skin Enterprises (NUS) has a market cap of $2.3 billion. It rose by 1.4% to close at $40.69 per share on June 15, 2016.

    By Gabriel Kane
  • uploads///nus pm
    Company & Industry Overviews

    Nu Skin Enterprises Continues to Rise

    Nu Skin Enterprises (NUS) has a market cap of $2.5 billion. It rose by 10.4% to close at $44.90 per share on June 16, 2016.

    By Gabriel Kane
  • uploads///nus pm
    Company & Industry Overviews

    Why Jefferies Rated Nu Skin Enterprises a ‘Hold’

    Nu Skin Enterprises (NUS) has a market cap of $2.3 billion. It fell by 0.22% to close at $41.26 per share on June 3, 2016.

    By Gabriel Kane
  • uploads///Portfolio Breakdown of the ELGAX
    Fund Managers

    How ELGAX’s Portfolio Has Changed

    Information technology was the single largest sectoral holding of ELGAX, forming 40% of its portfolio, as of April 2016.

    By David Ashworth
  • uploads///Sectoral Allocation of the ELGAX
    Fund Managers

    Helpful Facts about the Columbia Select Large Cap Growth Fund

    The Columbia Select Large Cap Growth Fund invests at least 80% of its assets in common stocks of US-based and foreign companies with market caps in the range of companies in the Russell 1000 Growth Index.

    By David Ashworth
  • uploads///analytical instruments segmentation
    Company & Industry Overviews

    Thermo Fisher Scientific’s Analytical Instruments Business Segment

    Thermo Fisher Scientific’s Analytical Instruments segment earned revenues of ~$3.3 billion in 2014, representing organic growth of around 4%.

    By Sarah Collins
  • uploads///specialty diagnostics
    Company & Industry Overviews

    Specialty Diagnostics Segment of Thermo Fisher Scientific

    A leading provider of diagnostic products and services, Thermo Fisher Scientific (TMO) has witnessed strong recurring revenues and high margins in the Specialty Diagnostics Segment over the years.

    By Sarah Collins
  • uploads///MEDICAL SPENDING V
    Company & Industry Overviews

    Analyzing Cost Structure for Medical Device Companies

    As per the US Census, spending on medical devices in the US has been constant for over a decade between 2005 to 2015.

    By Sarah Collins
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Mylan Topped Large-Caps with New Launches, Share Repurchase Plan

    Mylan (MYL) stock rose 6.4% for the week ended November 20, 2015. It went up on a couple of new drug launches and a share repurchase plan.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Illumina Continued to Rise, Led the Large-Cap Stocks

    Illumina (ILMN) rose by 2.7% on November 16, 2015. It rose for the fourth consecutive trading session. Illumina rose 10% in the trailing five-day period.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Illumina’s Market Expansion Strategy for Genome Sequencing

    Illumina’s Market Expansion Strategy includes targeting the United States, Europe, and China for population sequencing projects.

    By Margaret Patrick
  • uploads///Grah
    Company & Industry Overviews

    Illumina’s Key Products

    Illumina’s key products are based on the company’s NGS (next-generation sequencing) technologies.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Is Illumina Penetrating the Oncology Market?

    Illumina is targeting opportunities worth $12 billion in the oncology market, which can be broken down into research, translational, and clinical segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Illumina: Investor’s Overview of a Leading Biotechnology Company

    An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Top Ten of XBI Outperform by Market Cap

    The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.

    By Peter Neil
  • uploads///purch
    Fund Managers

    Analyzing Viking Global Investors’ Positions in 4Q14

    Viking Global Investors is an US-based hedge fund. The total value of Viking Global’s US long portfolio decreased to $21.78 billion in 4Q14.

    By Adam Rogers
  • uploads///ILLUMINA GOBAL REV
    Fund Managers

    Why Illumina’s outlook is so bright

    Illumina’s outlook is outstanding, as it has posted excellent 3Q14 results and its earnings continue to be bullish.

    By Adam Rogers
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.